The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cue Biopharma Inc shares valued at $30,900 were purchased by PASSERI DANIEL R on Dec 16 ’24. At $1.03 per share, PASSERI DANIEL R acquired 30,000 shares. The insider’s holdings grew to 164,578 shares worth approximately $0.11 million following the completion of this transaction.
As published in their initiating research note from Jefferies on March 13, 2024, Cue Biopharma Inc [CUE] has been a Buy and the price target has been revised to $6. As of November 21, 2022, Piper Sandler has initiated its “an Overweight” rating for CUE. Earlier on January 13, 2022, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for CUE stock.
Analyzing CUE Stock Performance
On last trading session,, Cue Biopharma Inc [NASDAQ: CUE] rose 13.00% to $0.66. The stock’s lowest price that day was $0.5406, but it reached a high of $0.669 in the same session. During the last five days, there has been a surge of approximately 2.58%. Over the course of the year, Cue Biopharma Inc shares have dropped approximately -39.86%. Shares of the company reached a 52-week high of $1.7500 on 01/06/25 and a 52-week low of $0.5406 on 06/18/25.
Support And Resistance Levels for Cue Biopharma Inc (CUE)
According to the 24-hour chart, there is a support level at 0.5744, which, if violated, would cause prices to drop to 0.4933. In the upper region, resistance lies at 0.7028. The next price resistance is at 0.7501. RSI (Relative Strength Index) is 48.97 on the 14-day chart, showing neutral technical sentiment.
Is Cue Biopharma Inc subject to short interest?
Stocks of Cue Biopharma Inc saw a sharp steep in short interest on 2025-05-30 dropping by 92916.0 shares to 0.77 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 0.87 million shares. A decline of -12.0% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.93 of the overall float, the days-to-cover ratio (short ratio) decline to 4.93.
Which companies own the most shares of Cue Biopharma Inc (CUE)?
In terms of Cue Biopharma Inc share price expectations, FactSet research, analysts set an average price target of 4 in the next 12 months, up nearly 589.66% from the previous closing price of $0.58. Analysts anticipate Cue Biopharma Inc stock to reach 7 by 2025, with the lowest price target being 2. In spite of this, 1 analysts ranked Cue Biopharma Inc stock as Buy at the end of 2025. On January 03, 2022, Craig Hallum assigned a price target of “a Buy” to the stock and initiated coverage with a $28.
